ATAD2 and hepatocellular carcinoma: Immunohistochemical (IHC) staining of a small subset of this patient cohort (n = 9; HCC and paired non-tumor liver) further validated the over-expression of ATAD2 protein in five out of these nine HCC patients (55.6%) (Figure 1C).